Ascentage Pharma to Participate in Evercore China Biotech Summit
Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced its participation in the upcoming Evercore China Biotech Summit scheduled for August 19-21, 2025 in Shanghai, China.
The company's management will engage in a fireside chat with the Evercore ISI Research team and conduct one-on-one meetings with investors during the conference. Interested investors can arrange meetings through their Evercore representatives.
Ascentage Pharma (NASDAQ: AAPG), un'azienda biofarmaceutica globale specializzata in trattamenti oncologici, ha annunciato la sua partecipazione al prossimo Evercore China Biotech Summit, che si terrà dal 19 al 21 agosto 2025 a Shanghai, Cina.
Il management dell'azienda parteciperà a una conversazione informale con il team di ricerca Evercore ISI e terrà incontri individuali con gli investitori durante la conferenza. Gli investitori interessati possono organizzare gli incontri tramite i loro rappresentanti Evercore.
Ascentage Pharma (NASDAQ: AAPG), una empresa biofarmacéutica global enfocada en tratamientos contra el cáncer, ha anunciado su participación en la próxima Evercore China Biotech Summit programada del 19 al 21 de agosto de 2025 en Shanghái, China.
La dirección de la empresa participará en una charla informal con el equipo de investigación de Evercore ISI y realizará reuniones individuales con inversores durante la conferencia. Los inversores interesados pueden coordinar reuniones a través de sus representantes de Evercore.
Ascentage Pharma (NASDAQ: AAPG)는 암 치료에 중점을 둔 글로벌 바이오제약 회사로, 2025년 8월 19일부터 21일까지 중국 상하이에서 열리는 Evercore China Biotech Summit에 참여할 것이라고 발표했습니다.
회사의 경영진은 Evercore ISI 리서치 팀과의 대화 세션에 참여하고, 컨퍼런스 기간 동안 투자자들과 일대일 미팅을 진행할 예정입니다. 관심 있는 투자자들은 Evercore 담당자를 통해 미팅을 예약할 수 있습니다.
Ascentage Pharma (NASDAQ : AAPG), une société biopharmaceutique mondiale spécialisée dans les traitements contre le cancer, a annoncé sa participation au prochain Evercore China Biotech Summit prévu du 19 au 21 août 2025 à Shanghai, en Chine.
La direction de l'entreprise participera à une discussion informelle avec l'équipe de recherche Evercore ISI et organisera des réunions individuelles avec les investisseurs lors de la conférence. Les investisseurs intéressés peuvent planifier des rencontres via leurs représentants Evercore.
Ascentage Pharma (NASDAQ: AAPG), ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Krebsbehandlungen, hat seine Teilnahme am bevorstehenden Evercore China Biotech Summit angekündigt, der vom 19. bis 21. August 2025 in Shanghai, China, stattfindet.
Das Management des Unternehmens wird an einem Gespräch mit dem Evercore ISI Forschungsteam teilnehmen und während der Konferenz Einzelgespräche mit Investoren führen. Interessierte Investoren können Treffen über ihre Evercore-Vertreter arrangieren.
- None.
- None.
ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company's management will participate in the Evercore China Biotech Summit being held on August 19 - 21, 2025 in Shanghai, China.
Management will be participating in a fireside chat moderated by the Evercore ISI Research team and one-on-one investor meetings at the conference. Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their Evercore representative.
About Ascentage Pharma Group International
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL just received approval by China’s National Medical Products Administration (NMPA). The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute projections by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of these statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless as may otherwise be required by law.
Contacts
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Jon Yu
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 677-1855
FAQ
When is Ascentage Pharma (AAPG) presenting at the Evercore China Biotech Summit 2025?
How can investors meet with Ascentage Pharma management at the Evercore conference?
What type of presentations will Ascentage Pharma (AAPG) give at the Evercore Biotech Summit?
Where is the Evercore China Biotech Summit 2025 being held?
